2601 Fourth Avenue
United States - Map
Oncothyreon Inc, a clinical-stage biopharmaceutical company, develops therapeutic products for the treatment of cancer. Its product candidate includes Tecemotide, a vaccine for the treatment of non-small cell lung cancer. The company is also developing ONT-10, a cancer vaccine, which is in Phase I clinical trial for use in various cancer indications, including breast, thyroid, colon, stomach, pancreas, ovarian, and prostate cancers, as well as various lung cancer; ONT-380, a small-molecule HER2 inhibitor that is in Phase Ib trial for the treatment of metastatic breast cancer, including patients with brain metastases; and PX-866, which has completed two Phase II trials for the treatment of various cancers. In addition, it develops PET lipid-A, a proprietary synthetic lipid-A analog. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.
|Oncothyreon Inc’s ISS Governance QuickScore as of Jul 1, 2013 is 9. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 7; Compensation: 6.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Robert L. Kirkman M.D.,
Chief Exec. Officer, Pres and Director
|Ms. Julia M. Eastland ,
Chief Financial Officer, Principal Accounting Officer, VP of Corp. Devel. and Sec.
|Mr. Gary Christianson ,
Chief Operating Officer
|Dr. Scott Robert Peterson Ph.D.,
Chief Scientific Officer and VP of R&D
|Dr. Diana Hausman M.D.,
Chief Medical Officer and VP of Clinical Devel.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|